ES2169783T3 - Metodos para mejorar la tolerancia de aloinjertos o xenoinjertos por administracion de proteinas de fijacion lfa-3 o cd2. - Google Patents

Metodos para mejorar la tolerancia de aloinjertos o xenoinjertos por administracion de proteinas de fijacion lfa-3 o cd2.

Info

Publication number
ES2169783T3
ES2169783T3 ES96117245T ES96117245T ES2169783T3 ES 2169783 T3 ES2169783 T3 ES 2169783T3 ES 96117245 T ES96117245 T ES 96117245T ES 96117245 T ES96117245 T ES 96117245T ES 2169783 T3 ES2169783 T3 ES 2169783T3
Authority
ES
Spain
Prior art keywords
tolerance
xenoinjertos
aloinjertos
administration
improve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96117245T
Other languages
English (en)
Inventor
Barbara Wallner
Christopher Benjamin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of ES2169783T3 publication Critical patent/ES2169783T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2824—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROTEINA QUE UNE CD2, QUE ES UN DERIVADO DE UN POLIPEPTIDO LFA3 SOLUBLE, SIENDO EL DERIVADO UNA FUSION DE INMUNOGLOBULINA QUE INCLUYE EL POLIPEPTIDO LFA-3 FUSIONADO CON UNA ZONA DE INMUNOGLOBULINA, O ESTANDO EL POLIPEPTIDO LFA-3 SOLUBLE UNIDO A UN AGENTE FARMACEUTICO, Y QUE SE UTILIZA EN LA PREPARACION DE UN MEDICAMENTO PARA UTILIZAR EN UN METODO DE MEJORAR LA TOLERANCIA DEL TEJIDO ALOINJERTADO O XENOINJERTADO TRASPLANTADO EN UN MAMIFERO, INCLUYENDO UN SER HUMANO, DE FORMA QUE EL METODO INCLUYE EL IMPLANTE EN EL MAMIFERO DE UN ALOINJERTO O XENOINJERTO Y LA ADMINISTRACION DE LA PROTEINA.
ES96117245T 1991-10-07 1992-10-06 Metodos para mejorar la tolerancia de aloinjertos o xenoinjertos por administracion de proteinas de fijacion lfa-3 o cd2. Expired - Lifetime ES2169783T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77270591A 1991-10-07 1991-10-07
US85070692A 1992-03-12 1992-03-12

Publications (1)

Publication Number Publication Date
ES2169783T3 true ES2169783T3 (es) 2002-07-16

Family

ID=27118640

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96117245T Expired - Lifetime ES2169783T3 (es) 1991-10-07 1992-10-06 Metodos para mejorar la tolerancia de aloinjertos o xenoinjertos por administracion de proteinas de fijacion lfa-3 o cd2.

Country Status (9)

Country Link
EP (2) EP0607353A1 (es)
JP (2) JPH07502495A (es)
AT (1) ATE210454T1 (es)
AU (1) AU678141B2 (es)
CA (1) CA2120731C (es)
DE (1) DE69232295T2 (es)
DK (1) DK0786255T3 (es)
ES (1) ES2169783T3 (es)
WO (1) WO1993006852A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
WO1993006866A2 (en) * 1991-10-07 1993-04-15 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the cd2/lfa-3 interaction
AU2006202939B2 (en) * 1994-03-08 2008-11-20 Dana-Farber Cancer Institute, Inc. Methods of modulating T cell unresponsiveness
EP1025856A3 (en) * 1994-03-08 2002-10-16 Dana-Farber Cancer Institute Methods for modulating T Cell unresponsiveness
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
EP1637155A1 (en) * 1998-08-31 2006-03-22 Biogen Idec MA Inc. Method of mudulating memory effector T-cells using a CD2-binding agent, and compositions
CZ298238B6 (cs) * 1998-08-31 2007-08-01 Astellas Us Llc Pouzití CD2 vazebného cinidla pro výrobu léku k modulaci pametových T bunek
WO2000045842A2 (en) * 1999-02-04 2000-08-10 The General Hospital Corporation Methods for human allografting
AU2002320352A1 (en) 2001-07-24 2003-02-17 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
WO2005115436A1 (en) 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
CN112236446A (zh) * 2018-03-29 2021-01-15 弗埃塞股份有限公司 Lfa3变体及其组合物与用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE260880T1 (de) * 1986-09-11 1988-11-03 Dana-Farber Cancer Institute, Inc., Boston, Mass., Us Verfahren zur ausloesung der zytotoxizitaet.
DE3886237T2 (de) * 1987-02-26 1994-05-05 Dana Farber Cancer Inst Inc Reinigung von LFA-3.
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
CA2049931A1 (en) * 1990-01-24 1991-07-25 Barbara P. Wallner Lfa-3 as a vaccine adjuvant
ES2147178T3 (es) * 1991-03-12 2000-09-01 Biogen Inc Dominio de union a cd2 del antigeno 3 asociado con la funcion linfocitica.
WO1993006866A2 (en) * 1991-10-07 1993-04-15 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the cd2/lfa-3 interaction

Also Published As

Publication number Publication date
CA2120731A1 (en) 1993-04-15
WO1993006852A2 (en) 1993-04-15
DE69232295D1 (de) 2002-01-24
ATE210454T1 (de) 2001-12-15
EP0607353A1 (en) 1994-07-27
WO1993006852A3 (en) 1993-07-22
DK0786255T3 (da) 2002-04-15
JP2003128579A (ja) 2003-05-08
JPH07502495A (ja) 1995-03-16
DE69232295T2 (de) 2002-07-18
EP0786255B1 (en) 2001-12-12
AU2889192A (en) 1993-05-03
AU678141B2 (en) 1997-05-22
EP0786255A1 (en) 1997-07-30
CA2120731C (en) 2008-08-19

Similar Documents

Publication Publication Date Title
Yoo et al. Induction of arthritis in monkeys by immunization with type II collagen.
ES2169783T3 (es) Metodos para mejorar la tolerancia de aloinjertos o xenoinjertos por administracion de proteinas de fijacion lfa-3 o cd2.
DE69010206D1 (de) Stabilisierte protein- oder peptidkonjugate.
ES2080838T3 (es) Conjugados de anticuerpos especificos del receptor de transferrina y agentes neurofarmaceuticos.
CA2355976A1 (en) Vascular endothelial cell growth factor antagonists and uses thereof
BR9915852A (pt) Conjugado de hapteno-portador para tratamento e prevenção do vìcio da nicotina
DK0527835T3 (da) Doseringsform til afgivelse af et anti-Parkinsonmiddel
UY23665A1 (es) Procedimiento para la preparacion de compuesto farmaceutico
EP0330227A3 (en) Derivatives of soluble t-4
JPH01100133A (ja) 包外摘出後の後水晶体包の混濁化を防止する有糸分裂抑制剤及び方法
DK0621786T3 (da) Induceret tolerance over for xenotransplantater
Rao et al. Analysis of proteins of bovine lens, vitreous, and aqueous by electrophoresis and by Oudin's gel diffusion technique
ES2115618T3 (es) Uso de anticuerpos anti-icam en la preparacion de un medicamento para el tratamiento del choque por endotoxinas.
DE69030522D1 (de) Lymphozyten-assoziiertes Zelloberflächenprotein
ATE113470T1 (de) Gehirnspezifische zubereitung mit gesteuerter abgabe.
AU5979201A (en) Methods of blocking tissue destruction by autoreactive t cells
AU3757789A (en) Method for delivery of therapeutic agents to target brain tissue using monoclonal antibody conjugates
ES2079851T3 (es) Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas.
BR9509433A (pt) Uso de (r-(z))-a-(metaxoiimino)-a-(1-azabiciclo-(2,2,2)oct-3-il)acetonitrila ou um sal farmaceuticamente aceitável da mesma processo para aperfeiçoar o processamento de uma proteina precursora de amilóide ao longo de um percurso não amiloidogênio processo para tratamento ou profilaxia do mal de alzheimer composição farmacêutica e uso processo ou composição
Kerwar et al. Passive transfer of arthritis by purified anticollagen immunoglobulin: localization of 125I-labeled antibody
DE58904108D1 (de) Arzneimittel.
PT89224A (pt) Processo para a preparacao de peptidos para o bloqueamento da actividade do pai-1 no sangue humano e sua utilizacao na preparacao de anticorpos
PT92071A (pt) Processo de preparacao de imunotoxinas e de preparados farmaceuticos para o tratamento ou profilaxia de doencas auto-imunes
Hyder et al. Humoral responses to type I collagen after surgical curettage procedures employing bovine collagen implants
JPH05238941A (ja) 薬剤組成物

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 786255

Country of ref document: ES